Scotiabank Sticks to Their Buy Rating for Legend Biotech (LEGN)
Buy Rating on Legend Biotech: Strong Carvykti Sales and High Market Potential Signal Upside
Legend Biotech Analyst Ratings
The Latest Analyst Ratings For Legend Biotech
TD Cowen Adjusts Legend Biotech Price Target to $67 From $71, Maintains Buy Rating
Legend Biotech Analyst Ratings
Truist Financial Remains a Buy on Legend Biotech (LEGN)
Analysts Offer Insights on Healthcare Companies: R1 RCM (RCM), Legend Biotech (LEGN) and Intuitive Surgical (ISRG)
Buy Rating Affirmed for Legend Biotech Amid Promising Carvykti Trial Results and Expert Endorsements
Buy Rating on Legend Biotech: CARVYKTI's Clinical Success and Expanding Manufacturing Capacity
Scotiabank Keeps Their Buy Rating on Legend Biotech (LEGN)
Legend Biotech Analyst Ratings
Legend Biotech Analyst Ratings
Legend Biotech Analyst Ratings
Legend Biotech Analyst Ratings
Legend Biotech Analyst Ratings
Jefferies Issues a Buy Rating on Legend Biotech (LEGN)
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Merus (MRUS) and Agilon Health (AGL)
Legend Biotech Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Legend Biotech (LEGN) and Singular Genomics Systems (OMIC)